Tenax Therapeutics to Present at the 36th Annual Roth Conference
Tenax Therapeutics, Inc. (Nasdaq: TENX) will participate in the 36th Annual Roth Conference to provide an update on the development of levosimendan, a cardiovascular and pulmonary disease treatment. CEO Chris Giordano will present on March 18, 2024, offering investors insights into the company's progress.
03/12/2024 - 08:30 AM
CHAPEL HILL, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will participate in the 36th Annual Roth Conference in Dana Point, California, from March 17-19, 2024. Tenax’s CEO, Chris Giordano, will provide an update on the company and the ongoing development of levosimendan, in a conference session investors can attend in person, or via webcast.
Format: Fireside Chat Presenter: Chris Giordano, President & Chief Executive OfficerDate and time: March 18, 2024 at 3:00 pm PDT Location: The Ritz-Carlton, Laguna NiguelWebcast: Click here
Tenax Therapeutics’ management will also participate in one-on-one investor meetings. Attendees may request meetings during the conference by contacting their Roth representative.
The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company owns global rights to develop and commercialize levosimendan. Tenax also is developing a unique oral formulation of imatinib. For more information, visit www.tenaxthera.com. Tenax’s common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.
Contacts
Investor Contact:
Brian Mullen
When will Tenax Therapeutics participate in the 36th Annual Roth Conference?
Tenax Therapeutics will participate in the 36th Annual Roth Conference from March 17-19, 2024.
What is the focus of Tenax Therapeutics as a pharmaceutical company?
Tenax Therapeutics focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases with high unmet medical needs.
Who will provide an update on the ongoing development of levosimendan at the conference?
CEO Chris Giordano will provide an update on the ongoing development of levosimendan at the conference.
How can investors attend the conference session by Tenax Therapeutics?
Investors can attend the conference session in person at The Ritz-Carlton, Laguna Niguel, or via webcast.
Where can attendees access the live and archived webcast of the presentation?
Attendees can access the live and archived webcast of the presentation from Tenax Therapeutics' investor relations webpage.
